Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; potato starch; lactose monohydrate; ascorbyl palmitate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, livial should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). livial should only be continued for as long as the benefit outweighs the risks.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - remeron (mirtazapine) tablets are indicated for the treatment of major depressive disorder. the efficacy of remeron in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. the effectiveness of remeron in hospitalize

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 120 mg - etoricoxib - arcoxia 120 mg tablets are indicated for the symptomatic relief of the pain and signs of inflammation associated with acute gouty arthritis.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 120 mg - etoricoxib - arcoxia 120 mg tablets are indicated for the symptomatic relief of the pain and signs of inflammation associated with acute gouty arthritis.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 60 mg - etoricoxib - arcoxia 60 mg tablets are indicated for the symptomatic relief of osteoarthritis (oa), rheumatoid arthritis (ra) and ankylosing spondylitis.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 60 mg - etoricoxib - arcoxia 60 mg tablets are indicated for the symptomatic relief of osteoarthritis (oa), rheumatoid arthritis (ra) and ankylosing spondylitis.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 90 mg - etoricoxib - arcoxia 90 mg tablets are indicated for the symptomatic relief of rheumatoid arthritis (ra) and ankylosing spondylitis.for the short-term treatment of moderate pain associated with dental surgery.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 90 mg - etoricoxib - arcoxia 90 mg tablets are indicated for the symptomatic relief of rheumatoid arthritis (ra) and ankylosing spondylitis.for the short-term treatment of moderate pain associated with dental surgery.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - ethinylestradiol; etonogestrel - vaginal ring - ethinylestradiol 2.7 mg; etonogestrel 11.7 mg - ethinylestradiol - contraception. the safety and efficacy has been established in women aged 18 to 40 years.

United States - English - NLM (National Library of Medicine)

organon llc - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - singulair® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. singulair is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions (5.1)] , reserve use for patients who have an inadequate response or intolerance to alternative therapies. singulair is not indicated for the treatment of an acute asthma attack. singulair is contraindicated in patients with hypersensitivity to any of its components. risk summary available data from published prospective and retrospective cohort studies over decades with montelukast use in pregnant women have not estab